Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial

Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial

Abstract Aims To report the mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) and reading performance (reading acuity and maximum reading speed (MRS) using the MNREAD test) between baseline and 24 months in treatment-naïve patients with neovascular...

Full description

Bibliographic Details
Main Authors: Praveen J. Patel, Hari Jayaram, Maria Eleftheriadou, Clara Vazquez-Alfageme, Niaz Islam, Gary S. Rubin, Bishwanath Pal, Peter K. Addison, Robin Hamilton, Simona Degli Esposti
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-06-01
Series:Ophthalmology and Therapy
Subjects:
Aflibercept
Neovascular age-related macular degeneration
Reading ability
Treat and extend
Online Access:https://doi.org/10.1007/s40123-020-00267-5

Internet

https://doi.org/10.1007/s40123-020-00267-5

Similar Items